Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

United Therapeutics (UTHR) FCF Margin (2016 - 2025)

United Therapeutics' FCF Margin history spans 17 years, with the latest figure at 73.08% for Q4 2025.

  • For Q4 2025, FCF Margin rose 440979.0% year-over-year to 73.08%; the TTM value through Dec 2025 reached 45.4%, down 1576.0%, while the annual FY2025 figure was 45.4%, 5.0% up from the prior year.
  • FCF Margin for Q4 2025 was 73.08% at United Therapeutics, up from 35.11% in the prior quarter.
  • Across five years, FCF Margin topped out at 73.08% in Q4 2025 and bottomed at 4490.0% in Q4 2023.
  • The 5-year median for FCF Margin is 38.34% (2021), against an average of 403.29%.
  • The largest annual shift saw FCF Margin crashed -451594bps in 2023 before it surged 440979bps in 2025.
  • A 5-year view of FCF Margin shows it stood at 42.12% in 2021, then plummeted by -38bps to 25.94% in 2022, then crashed by -17409bps to 4490.0% in 2023, then rose by 3bps to 4336.71% in 2024, then skyrocketed by 102bps to 73.08% in 2025.
  • Per Business Quant, the three most recent readings for UTHR's FCF Margin are 73.08% (Q4 2025), 35.11% (Q3 2025), and 25.09% (Q2 2025).